B7-H1-targeted immunotherapy for head and neck cancer

Bibliography

• BYERS RIVI: Dr Martin: how are we doing in 2000? Arch. Otolaryngol. Head Neck Surg. (2001) 127:759–765.
   Web of Science ®Google Scholar
• HOFFMAN HT, KARNELL LH, FUNK GF, ROBINSON RA,MENCK HR: The national cancer database report on cancer of the head and neck. Arch. Otolaryngol. Head Neck Surg. (1998) 124:951–962.
   PubMedGoogle Scholar
• STROME SE, WEINMAN EC: Advanced larynx cancer. Curi: Treat. Options Oncol. (2002) 3(1):11–20.
   PubMedGoogle Scholar
• GRANER DE, FOOTE RL,KASPERBAUERJL et al.: Swallow function in patients before and after intra-arterial chemoradiation. Laryngoscope (2003) 113:573–579.
   Google Scholar
• COOPER JS, PAJAK TF,FORASTIERE AA et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl. I Med. (2004) 350:1937–1944.
   Google Scholar
• LOWE VJ, DUNPHY F, VARVARES M et al.: Prediction of chemotherapy response in patients with advanced head and neck cancer using [18F] fluoro-deoxyglucose positron emission tomography (FDG-PET). Head Neck (1997) 19:666–674.
   PubMedGoogle Scholar
• THOMAS SM, GRANDIS JR: Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev (2004) 30(3):255–268.
   PubMed Web of Science ®Google Scholar
• ROBERT F, EZEKIEL MP, SPENCER SAet al.: Phase I study of anti-epidermal growth factor receptor antibody cetwdmab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19(13):3234–3243.
   Google Scholar
• CHEN L, LINSLEY PS,HELLSTROM KE: Costimulation ofT cells for tumor immunity. Immunol. Today (1993) 13:483–486.
   Google Scholar
• CHEN L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev Immunol. (2004) 4:336–347.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, LEDBETTER JA: The role ofthe CD28 receptor during T cell response to antigen. Anna. Rev Immunol. (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Anna. Rev Immunol. (1996) 14:233–258.
   PubMed Web of Science ®Google Scholar
• KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl. J. Med. (2003) 349(20):1907–1915.
   PubMed Web of Science ®Google Scholar
• HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Nati Acad. Sci. USA (2003) 100(8):4712–4717.
   PubMed Web of Science ®Google Scholar
• ••The first clinical evidence thatCTLA-4 blockade increases the antitumour immunity.
   Google Scholar
• PHAN GQ, YANG JC, SHERRY RIVI et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Nati Acad. Si". USA (2003) 100(14):8372–8377.
   Google Scholar
• ••This study demonstrated thatantitumour immune response induced by CTLA-4 blockade was accompanied by significant autoimmunity.
   Google Scholar
• DONG H, ZHU G, TAMADA K,CHEN L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. (1999) 5:1365–1369.
   PubMed Web of Science ®Google Scholar
• •This study identifies B7-H1 as a new member of the B7 family with costimulatory function.
   Google Scholar
• FREEMAN GJ, LONG AJ, IWAI Y et al.:Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. I Exp. Med. (2000) 192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• •This study shows that PD-1 is a receptor for B7-H1 and mediates the suppressive function of B7-H1 on lymphocyte activation.
   Google Scholar
• SICA GL, CHOI IH, ZHU GF et al.: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 18(6):849–861.
   PubMed Web of Science ®Google Scholar
• CHAPOVAL Al, NI J, LAU JS et al.: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. (2001) 2(3):269–274.
   PubMed Web of Science ®Google Scholar
• DONG H, STROME SE, SALOMAO DR et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism ofExpert Op/n. Biol. Ther. (2004) 4(10) immune evasion. Nat. Med. (2002) 8(8):793–800.
   Google Scholar
• ••This paper demonstrates thebroad expression of B7-H1 on human tumour tissue and cell lines, and details its functional consequences. It provides evidence that B7-H1 could be a potential target for manipulation in cancer irnmunotherapy.
   Google Scholar
• NAKAZAWA A, DOTAN I, BRIMNES J et al: The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 126(5):1347–1357.
   PubMed Web of Science ®Google Scholar
• EPPIHIMER MJ, GUNN J,FREEMAN GJ et al.: Expression and regulation of the PD-Li immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 9(2):133–145.
   Google Scholar
• MAZANET MM, HUGHES CC: B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. Inonunol. (2002) 169(7):3581–3588.
   Google Scholar
• RODIG N, RYAN T, ALLEN JA et al.: Endothelial expression of PD-Li and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur: Inonunol. (2003) 33(11):3117–3126.
   Google Scholar
• ZHANG X, SCHWARTZ JC, GUO X et al: Structural and functional analysis of the costimulatory receptor programmed death-1. brununio, (2004) 20(3):337–347.
   Google Scholar
• LATCHMAN Y, WOOD CR,CHERNOVA T et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Inonunol. (2001) 2(3):261–268.
   Google Scholar
• OKAZAKI T, MAEDA A,NISHIMURA H, KUROSAKI T, HONJO T: PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Nati Acad. Sci USA (2001) 98(24):13866–13871.
   PubMed Web of Science ®Google Scholar
• SHLAPATSKA LM, MIKHALAP SV, BERDOVA AG et al: CD150 association with either the 5H2-containing inositol phosphatase or the 5H2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. I Innnunol. (2001) 166(9):5480–5487.
   Google Scholar
• KHOURY SJ, SAYEGH MH: The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. brununio, (2004) 20(5):529–538.
   Google Scholar
• NISHIMURA H, NOSE M, HIAI H, MINATO N, HONJO T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (i999) 11(2):141–151.
   Google Scholar
• NISHIMURA H, OKAZAKI T, TANAKA Y et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 291(5502)319–322.
   Google Scholar
• GAO W, DEMIRCI G, STROM TB, LI XC: Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation (2003) 76(6):994–999.
   PubMed Web of Science ®Google Scholar
• CARTER LL, FOUSER LA, JUSSIF J et al.: PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur. Inonunol. (2002) 32(3):634–643.
   Google Scholar
• BROWN JA, DORFMAN DM, MA FR et al.: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J.Immunol. (2003) 170(3):1257–1266.
   PubMed Web of Science ®Google Scholar
• SELENKO-GEBAUER N, MAJDIC 0, SZEKERES A et al: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. Innnunol. (2003) 170(7):3637–3644.
   Google Scholar
• CURIEL TJ, WEI S, DONG H et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. (2003) 9:562–567.
   PubMed Web of Science ®Google Scholar
• TSUSHIMA F, IWAI H, OTSUKI N et al: Preferential contribution of B7-H1 to programmed death-1 -mediated regulation of hapten-specific allergic inflammatory responses. Eur. Inonunol. (2003) 33(10):2773–2782.
   Google Scholar
• IWAI Y, TERAWAKI S, IKEGAWA M, OKAZAKI T, HONJO T: PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. (2003) 198(1):39–50.
   PubMed Web of Science ®Google Scholar
• WIENDL H, MITSDOERFFER M, SCHNEIDER D et al: Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB (2003) 17(13):1892–1894.
   PubMedGoogle Scholar
• OZKAYNAK E, WANG L,GOODEARL A et al: Programmed death-1 targeting can promote allograft survival. Inonunol. (2002) 169(11):6546–6552.
   Google Scholar
• BLANK C, BROWN I, PETERSON AC et al: PD-Ll/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TC12) transgenic CD8+ T cells. Cancer Res. (2004) 64(3):1140–1145.
   PubMed Web of Science ®Google Scholar
• IWAI Y, ISHIDA M, TANAKA Y et al: Involvement of PD-Li on tumor cells in the escape from host immune system and tumor immunotherapy by PD-Li blockade. Proc. Nati Acad. Sci. USA (2002) 99(19):12293–12297.
   PubMed Web of Science ®Google Scholar
• DONG H, ZHU G, TAMADA K et al.: B7-H1 determines accumulation and deletion of intrahepatic CD8(+)T lymphocytes. brununio, (2004) 20(3):327–336.
   Google Scholar
• TAMURA H, DONG H, ZHU G et al.: B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood (2001) 97(6):1809–1816.
   PubMed Web of Science ®Google Scholar
• KANAI T, TOTSUKA T,URAUSHIHARA K et al.: Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.Inonunol. (2003) 171(8):4156–4163.
   Google Scholar
• SUBUDHI SK, ZHOU P, YERIAN LM et al.: Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Invest. (2004) 113 (5):694–700.
   PubMed Web of Science ®Google Scholar
• DONG H, STROME SE,MATTESON EL et al.: Costimulating aberrant T cell responses by By-H1autoantibodies in rheumatoid arthritis. Clin. Invest. (2003) 111(3):363–370.
   Google Scholar
• WANG S, BAJORATH J, FLIES DB et al.: Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. Exp. Med. (2003) 197(9):1083–1091.
   PubMed Web of Science ®Google Scholar
• WINTTERLE S, SCHREINER B, MITSDOERFFER M et al.: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. (2003) 63(21):7462–7467.
   PubMed Web of Science ®Google Scholar
• SAUDEMONT A, QUESNEL B: In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood (2004) (In Press).
   Google Scholar
• STROME SE, DONG H, TAMURA H et al.: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. (2003) 63(19):6501–6505.
   PubMed Web of Science ®Google Scholar
• ••This paper reports that, in combinationwith adoptive transfer of activated tumour-reactive T cells, B7-H1 blockade prolongs the survival of mice harbouring squamous cell carcinoma tumours.
   Google Scholar
• LEE PP, YEE C, SAVAGE PA et al:Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. (1999) 5:677–685.
   PubMed Web of Science ®Google Scholar
• BERARD F, BLANCO P, DAVOUST J et al.: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. Exp. Med. (2000) 192(11):1535–1544.
   PubMed Web of Science ®Google Scholar
• PALUCKA AK, DHODAPKAR MV, PACZESNY S et al.: Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J. Inonunother. (2003) 26(5):432–439.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science (2002) 298(5594):850–854.
   PubMed Web of Science ®Google Scholar
• CHAPOVAL Al, ZHU G, CHEN L: Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules. Ma Biotechnol (2002) 21(3):259–264.
   Google Scholar
• DAVIS C, JIA X-C, FENG X,HAAK-FRENDSCHO M: Production of human antibodies from transgenic mice.In: Antibody Engineering. Lo BKC (Ed.), Humana Press, Totowa, NJ, USA (2003):191–200.
   Google Scholar
• STROME SE, VOSS S, WILCOX R et al.:Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. (2002) 62(6):1884–1889.
   PubMed Web of Science ®Google Scholar
• FEUERER M, BECKHOVE P, BAI L et al.: Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow.Nat. Med. (2001) 7(4):452–458.
   Google Scholar
• KIENSTRA MA, NEEL HB,STROME SE, ROCHE P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.Head Neck (2003) 25(6):457–463.
   Google Scholar
• STROME SE, CHEN L: Costimulation-based immunotherapy for head and neck cancer. Curt: Treat. Options Oncol (2004) 5:27–33.
   PubMedGoogle Scholar
• STROME SE, SAVVA A, BRISSETT AE et al: Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin. Cancer Res. (2002) 8:1093–1100.
   PubMed Web of Science ®Google Scholar
• WEINMAN EC, ROCHE PC,KASPERBAUER JL et al.: Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer (2003) 97(9):2203–2211.
   Google Scholar
• CHAKRABORTY NG, SPORN JR, TORTORA AF et al: Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Inonunol. Inonunother. (1998) 47:58–64.
   PubMed Web of Science ®Google Scholar
• DEN BROK MH, SUTMULLER RP, VAN DER VOORT R et al.: In situ tumor ablation creates an antigen source for the generation of antitumor immunity.Cancer Res. (2004) 64(11):4024–4029.
   Google Scholar
• WILCOX RA, TAMADA K,STROME SE, CHEN L: Signaling through NK cell-associated CD 137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. kifnunol. (2002) 169(8):4230–4236.
   Google Scholar
• WILCOX RA, FLIES DB, ZHU G et al.: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. (2002) 109(5):651–659.
   PubMed Web of Science ®Google Scholar
• NGUYEN LT, RADHAKRISHNAN S, CIRIC B et al.: Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. I Exp. Med. (2002) 196(10):1393–1398.
   PubMed Web of Science ®Google Scholar
• TOTSUKA T, KANAI T, IIYAMA R et al.:Ameliorating effect of anti-induciblecostimulator monoclonal antibody in a murine model of chronic colitis.Gastroenterology (2003) 124(2):410–421.Affiliation
   Google Scholar